WASHINGTON (dpa-AFX) - Accuray Inc. (ARAY), the premier radiation oncology company, said it has launched its new TomoTherapy H Series, featuring the TomoHDA System, with faster planning, faster delivery and increased quality.
The company stated that the new TomoEDGE dynamic jaws technology provides users with added flexibility in treatment delivery by sharpening dose fall off and accuracy. In many cases the use of TomoEDGE for head and neck tumors and prostate cancer treatments has resulted in the reduction of beam-on time by half. With the TomoHDA System this new technology is standard and can be applied to both TomoHelical and TomoDirec treatment modes for 3DCRT and IMRT deliveries.
Giving a brief description on the TomoHDA System, Accuray said it is a fully-integrated 3D image-guided, full spectrum radiation therapy system and builds upon the proven TomoTherapy Hi-Art and TomoHD technologies.
Also, the TomoHDA System offers multiple new benefits including performance enhancements, unrivaled dose distributions and faster treatments, the company added.
The TomoHDA System is part of the new TomoTherapy H Series. Included in this series of products, is the new TomoH System, the gold standard for image-guided IMRT treatment, providing streamlined 3D CT daily image guidance and ultrafast MLC modulation, enabling the delivery of the dose to achieve excellent target homogeneity while sparing surrounding healthy tissue.
Copyright RTT News/dpa-AFX
